TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis
USA - NASDAQ:TMDX - US89377M1099 - Common Stock
115.01 USD
-0.54 (-0.47%)
116 USD
+0.99 (+0.86%)
TMDX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. TMDX has an average financial health and profitability rating. TMDX is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, TMDX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
TMDX had negative earnings in 4 of the past 5 years.
TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of TMDX (9.71%) is better than 92.59% of its industry peers.
Looking at the Return On Equity, with a value of 25.88%, TMDX belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
TMDX's Return On Invested Capital of 8.72% is amongst the best of the industry. TMDX outperforms 87.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROIC | 8.72% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a better Profit Margin (16.22%) than 92.06% of its industry peers.
With an excellent Operating Margin value of 16.89%, TMDX belongs to the best of the industry, outperforming 86.77% of the companies in the same industry.
The Gross Margin of TMDX (60.28%) is better than 61.38% of its industry peers.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TMDX is still creating some value.
TMDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TMDX has more shares outstanding
Compared to 1 year ago, TMDX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.02 indicates that TMDX is not in any danger for bankruptcy at the moment.
The Altman-Z score of TMDX (5.02) is better than 78.31% of its industry peers.
The Debt to FCF ratio of TMDX is 4.27, which is a neutral value as it means it would take TMDX, 4.27 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 4.27, TMDX is doing good in the industry, outperforming 79.89% of the companies in the same industry.
A Debt/Equity ratio of 1.43 is on the high side and indicates that TMDX has dependencies on debt financing.
The Debt to Equity ratio of TMDX (1.43) is worse than 80.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Altman-Z | 5.02 |
ROIC/WACC1.09
WACC7.97%
2.3 Liquidity
A Current Ratio of 7.66 indicates that TMDX has no problem at all paying its short term obligations.
The Current ratio of TMDX (7.66) is better than 88.89% of its industry peers.
A Quick Ratio of 7.10 indicates that TMDX has no problem at all paying its short term obligations.
TMDX has a better Quick ratio (7.10) than 90.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 41.20%.
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
The Earnings Per Share is expected to grow by 44.52% on average over the next years. This is a very strong growth
Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 21.23% on average per year.
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 46.56, TMDX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than the industry average as 67.72% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 25.89, TMDX is valued quite expensively.
With a Price/Forward Earnings ratio of 39.41, TMDX can be considered very expensive at the moment.
70.90% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, TMDX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.56 | ||
| Fwd PE | 39.41 |
4.2 Price Multiples
69.84% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 78.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 32.67 | ||
| EV/EBITDA | 32.61 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.74% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
115.01
-0.54 (-0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change1.44%
Ins Owners2.96%
Ins Owner Change2.28%
Market Cap3.92B
Revenue(TTM)566.35M
Net Income(TTM)91.86M
Analysts83.16
Price Target149.33 (29.84%)
Short Float %24.1%
Short Ratio8.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-0.07%
PT rev (3m)-3.05%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-4.51%
EPS NY rev (1m)9.57%
EPS NY rev (3m)43.63%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)3.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.56 | ||
| Fwd PE | 39.41 | ||
| P/S | 6.92 | ||
| P/FCF | 32.67 | ||
| P/OCF | 22.03 | ||
| P/B | 11.04 | ||
| P/tB | 11.5 | ||
| EV/EBITDA | 32.61 |
EPS(TTM)2.47
EY2.15%
EPS(NY)2.92
Fwd EY2.54%
FCF(TTM)3.52
FCFY3.06%
OCF(TTM)5.22
OCFY4.54%
SpS16.61
BVpS10.41
TBVpS10
PEG (NY)0.29
PEG (5Y)N/A
Graham Number24.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROCE | 11.04% | ||
| ROIC | 8.72% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 19.58% | ||
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% | ||
| FCFM | 21.19% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Debt/EBITDA | 4.17 | ||
| Cap/Depr | 223.08% | ||
| Cap/Sales | 10.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.33% | ||
| Profit Quality | 130.63% | ||
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 | ||
| Altman-Z | 5.02 |
F-Score7
WACC7.97%
ROIC/WACC1.09
Cap/Depr(3y)950.14%
Cap/Depr(5y)614.59%
Cap/Sales(3y)35.03%
Cap/Sales(5y)23.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y204.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.49%
FCF growth 1Y186.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.62%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 46.56 and the Price/Book (PB) ratio is 11.04.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.